ADRENAL INSUFFICIENCY IN PRIMARY SYSTEMIC AMYLOIDOSIS

原发性系统性淀粉样变性的肾上腺功能不全

• 批准号: 6306729
• 负责人: JOHN L BERK
• 金额: $ 3.05万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6306729
• 关键词: adrenocorticotropic hormone; amyloidosis; blood chemistry; blood proteins; clinical research; cortisol; hormone biosynthesis; human subject; hypoadrenalism; medical complication

The Amyloid Treatment and Research Program is a large referral-based Center that processes over 200 patient visits annually and offers experimental therapies for patients with primary systemic disease. The ability to withstand significant stress is vital to the success of these therapies. We propose to define the prevalence of hypoadrenalism in patients with primary systemic amyloidosis by administering synthetic ACTH and measuring changes in serum cortisol levels.

淀粉样蛋白治疗和研究计划是一个大型的以美国为基础的中心，每年处理200多名患者就诊，并为原发性全身性疾病患者提供实验性治疗。 承受巨大压力的能力对于这些疗法的成功至关重要。 我们建议通过给予合成ACTH和测量血清皮质醇水平的变化来确定原发性系统性淀粉样变性患者肾上腺功能减退的患病率。